A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solid Tumours

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CEMIC, Buenos Aires, Argentina

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participant is an adult (according to the age of majority as defined by local regulations)
Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
Informed consent has been obtained from the participant or legally authorized representative, as per local regulations

Exclusion criteria

-Participant has a prior or current diagnosis of haematological malignancy

Treatment and study plan

Primary outcomes

Overall Survival

Time frame: From date of registry entry until death, for up to 5 years

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)

Important dates

Study start: 2020
Primary completion: 2026
Study completion: 2026
First posted: Aug 27, 2020
Registry last updated: May 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed